These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6140693)

  • 21. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
    Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
    Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
    Klimke A; Klieser E
    Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
    Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
    Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
    Thompson PA; Buckley PF; Meltzer HY
    J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perazine and carbamazepine in comparison to olanzapine in schizophrenia.
    Ohlmeier MD; Jahn K; Wilhelm-Gossling C; Godecke-Koch T; Hoffmann J; Seifert J; Emrich HM; Schneider U
    Neuropsychobiology; 2007; 55(2):81-8. PubMed ID: 17570951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The outpatient clinic for patients under chronic lithium or neuroleptic treatment as a phase-IV research tool.
    Pietzcker A; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1984 Sep; 17(5):162-7. PubMed ID: 6149570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].
    Leweke FM; Gerth CW; Koethe D; Nolden BM; Klosterkötter J
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):211-9. PubMed ID: 17230308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First month of neuroleptic treatment in schizophrenia: only partial normalization of the late positive components of visual ERP.
    Mintz M; Hermesh H; Glicksohn J; Munitz H; Radwan M
    Biol Psychiatry; 1995 Mar; 37(6):402-9. PubMed ID: 7772649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular irregularities in schizophrenia--more than an epiphenomenon?].
    Volz HP; Mackert A
    Nervenarzt; 1991 May; 62(5):298-302. PubMed ID: 1865961
    [No Abstract]   [Full Text] [Related]  

  • 34. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
    Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
    Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term clinical experience with clozapine].
    Gelly F; Chambon O; Marie-Cardine M
    Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions.
    Gaebel W; Riesbeck M; Janssen B; Schneider F; Held T; Mecklenburg H; Sass H
    Eur Arch Psychiatry Clin Neurosci; 2003 Aug; 253(4):175-84. PubMed ID: 12910348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia.
    Gaebel W; Müller-Oerlinghausen B; Schley J
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.